Bid for Allergan: Morgan Stanley gets a bitter pill
Pharma firm uses bankers' emails to put further pressure on Valeant
[NEW YORK] In its quest to defend against a US$53 billion hostile takeover, Allergan pulled back the veil on the usually secretive world of mergers and acquisitions banking on Monday.
Reiterating its belief that the business model of Valeant Pharmaceuticals is unsustainable, Botox-maker Allergan took the unusual step of publishing excerpts from emails written by senior investment bankers that it says bolsters its case.
Morgan Stanley is now advising Valeant, according to people briefed on the matter. But before it began working for Valeant, Morgan Stanley tried to get hired by Allergan.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Former PAP MP, minister of state retire as company directors
US: Wall St opens higher
Air China to buy 100 locally made C919 jets in US$11 billion deal
HCA beats first-quarter profit estimates on higher patient admissions
F&B operator YKGI to exclusively operate Chicha San Chen in Macau for next eight years
LMIRT Q1 net property income dips 3.1% to S$30 million on higher expenses